drugset
drugset / Trial / NCT05786937

Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals

NCT05786937 ↗

Phase 1 Unknown 30 enrolled University of Sao Paulo General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this interventional study is to validate the strategy of adjuvant therapy with dendritic cells in HIV infection in chronically infected individuals. The main questions it aims to answer are related to the safety and tolerance of the intervention and the virological and immunological impact of immunotherapy with aDC1 in HIV-infected individuals. The study will include 30 diagnosed HIV-infected patients, using antiretroviral therapy, who will be immunized with aDC1 or placebo according to the arms of this study: G1) placebo; G2) aDC1immunization; G3) aDC1 immunization with analytical treatment interruption of ART.

Timeline

Start
2023-06
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpha-type-1 Polarizing Dendritic Cells (aDC1) Cell therapy — —

Indications

No indication recorded.